Skip to main content


Health

"There is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients and health systems," an editorial in the medical journal the Lancet warns.
572 of 1555



Newsletter Sign Up

Daily Readings

Reading 1, Job 9:1-12, 14-16
Job spoke next. He said: Indeed, I know it is as you say: how ... Read More

Psalm, Psalms 88:10-11, 12-13, 14-15
Do you work wonders for the dead, can shadows rise up to praise ... Read More

Gospel, Luke 9:57-62
As they travelled along they met a man on the road who said to ... Read More

Saint of the Day

October 1 Saint of the Day

St. Therese of Lisieux
October 1: Generations of Catholics have admired this young saint, called ... Read More